Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00826280 · ClinicalTrials.gov registry record · Phase 3
Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 347
- Enrollment target
NCT00826280 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 347 participants.
The verdict
NCT00826280, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 347 participants
- Enrollment target
Study Summary
Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI
Interventions
- DRUG placebo
- DRUG regadenoson
- DRUG overencapsulated caffeine
- RADIATION technetium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2009-03-24 |
| Est. Completion | 2010-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00826280
The ClinicalTrials.gov registry entry for NCT00826280 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00826280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00826280 about?
NCT00826280 is a clinical study titled "Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)". Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI
What is the current status of trial NCT00826280?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 347 participants. The study started on 2009-03-24. Estimated completion is 2010-07-15.
What interventions are being tested in trial NCT00826280?
The interventions under investigation include: placebo (DRUG), regadenoson (DRUG), overencapsulated caffeine (DRUG), technetium (RADIATION).
Who is sponsoring clinical trial NCT00826280?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.